Immune

Immunoglobulin Testing for SIBO Patients: IgA, IgG, IgM, and Fecal sIgA

April 28, 202610 min readBy GLP1Gut Team
immunoglobulin testingIgAIgGIgMfecal sIgA

📋TL;DR: For SIBO patients with recurrent overgrowth, immunoglobulin testing can identify an underlying immune deficiency driving relapse. The serum immunoglobulin panel (IgA, IgG, IgM) is the standard first-line blood test. Low IgA alone suggests selective IgA deficiency. Low IgG with low IgA or IgM suggests CVID. Fecal secretory IgA (sIgA) measures mucosal immune output directly but is less standardized. Results should be interpreted by a physician, and patients with confirmed immunodeficiency patterns should be referred to clinical immunology.

What We Know

  • A serum immunoglobulin panel (IgA, IgG, IgM) is the standard screening test for primary immunodeficiency and is widely available.
  • Selective IgA deficiency (serum IgA below 7 mg/dL with normal IgG and IgM) is the most common primary immunodeficiency linked to SIBO.
  • CVID is diagnosed when IgG is significantly low (typically below 500 mg/dL) with low IgA and/or IgM and impaired vaccine responses.
  • Fecal secretory IgA can be measured in stool and reflects mucosal immune output, though reference ranges vary by lab.
  • Immunoglobulin replacement therapy (IVIG or subcutaneous Ig) is effective for CVID but does not replace IgA specifically.

What We Don't Know

  • Whether routine immunoglobulin screening improves outcomes in all recurrent SIBO patients or only those with specific clinical patterns.
  • The clinical utility of fecal sIgA as a standalone marker for SIBO risk prediction.
  • Optimal thresholds for fecal sIgA that reliably indicate clinically significant mucosal immune impairment.
  • Whether serum-derived bovine immunoglobulin supplements meaningfully improve mucosal immunity in IgA-deficient patients.
  • How often immunoglobulin levels should be rechecked in patients with borderline results.

When SIBO recurs despite appropriate antibiotic therapy and prokinetic support, the question shifts from how to treat the overgrowth to why it keeps returning. Immune deficiency is one of the most underinvestigated root causes. The good news is that screening for the most common immune deficiencies linked to SIBO requires only a standard blood draw. This guide walks through the available immunoglobulin tests, what each one measures, how to interpret the results, and when to escalate to a specialist.

The serum immunoglobulin panel: IgA, IgG, and IgM

The serum immunoglobulin panel is the first-line screening test for humoral (antibody-mediated) immune deficiency. It measures the circulating levels of three major immunoglobulin classes. IgA (normal range approximately 70-400 mg/dL in adults) is the primary mucosal immunoglobulin. Low serum IgA correlates with low secretory IgA in most patients. IgG (normal range approximately 700-1,600 mg/dL) is the most abundant serum immunoglobulin and the primary defense against bacterial and viral infections. IgG has four subclasses (IgG1-4), and subclass deficiencies can exist even when total IgG is normal. IgM (normal range approximately 40-230 mg/dL) is the first antibody produced in an immune response and plays a role in early bacterial defense.

The test requires a standard venous blood draw with no special preparation. Fasting is not required. Results are typically available within 2-5 business days. Most insurance plans cover this test when ordered with a clinical indication such as recurrent infections, chronic diarrhea, or suspected immunodeficiency. Any physician, including a gastroenterologist or primary care provider, can order a serum immunoglobulin panel.

Interpreting serum immunoglobulin results

The pattern of immunoglobulin abnormalities guides the differential diagnosis. A low IgA (below 7 mg/dL) with normal IgG and IgM indicates selective IgA deficiency, the most common primary immunodeficiency and a known SIBO risk factor. A low IgG (typically below 500 mg/dL) with low IgA and/or low IgM raises suspicion for CVID, which requires additional workup including vaccine response testing and lymphocyte subset analysis. A low IgG with normal IgA and IgM may indicate an IgG subclass deficiency, which can be evaluated with an IgG subclass panel. Normal values across all three immunoglobulins make primary humoral immunodeficiency unlikely, though they do not exclude mucosal-specific deficiency (measurable by fecal sIgA) or cellular immune defects.

PatternLikely DiagnosisNext Steps
Low IgA, normal IgG, normal IgMSelective IgA deficiencyConfirm on repeat testing; screen for celiac with IgG-based tests
Low IgG, low IgA and/or IgMPossible CVIDRefer to immunology for vaccine response and lymphocyte testing
Low IgG, normal IgA, normal IgMPossible IgG subclass deficiencyOrder IgG subclass panel (IgG1-4)
All normalPrimary humoral deficiency unlikelyConsider fecal sIgA or other SIBO root causes

Fecal secretory IgA (sIgA)

Fecal secretory IgA measures the IgA produced and secreted into the intestinal lumen. It is a functional marker of mucosal immune output rather than systemic immune status. This distinction matters because some patients have normal serum IgA but reduced mucosal sIgA production, or vice versa. Fecal sIgA testing is available through specialty and functional medicine labs (such as Genova Diagnostics, Doctor's Data, and Diagnostic Solutions). The test uses a stool sample, often collected as part of a comprehensive stool analysis. Reference ranges vary by lab but generally fall between 510 and 2,010 mcg/g. Values below the lab's reference range suggest impaired mucosal immune function. Values above the range may indicate active mucosal inflammation or infection.

The clinical utility of fecal sIgA in SIBO management is still emerging. It is not part of standard gastroenterology practice but is used more frequently in functional and integrative medicine settings. Low fecal sIgA in a patient with recurrent SIBO provides supportive evidence for an immune contribution to relapse, but it should not be used as the sole basis for diagnosis or treatment decisions. It is most useful when interpreted alongside serum immunoglobulin levels and clinical history.

When to refer to immunology

Not every abnormal immunoglobulin result requires immunology referral. Isolated selective IgA deficiency can usually be managed by a gastroenterologist or primary care provider, with immunology referral reserved for patients who develop frequent, severe, or unusual infections. However, several patterns warrant prompt immunology referral.

  • Low IgG (below 500 mg/dL) with or without low IgA/IgM, suggestive of CVID.
  • Low IgG subclasses with recurrent sinopulmonary infections.
  • Progressive decline in immunoglobulin levels on serial testing.
  • Recurrent infections requiring hospitalization or intravenous antibiotics.
  • Family history of primary immunodeficiency.
  • Concurrent autoimmune conditions with immunodeficiency pattern.
  • Any suggestion of combined immunodeficiency (low immunoglobulins plus low lymphocyte counts or abnormal lymphocyte subsets).

Supplement considerations

Patients and practitioners sometimes ask about supplements that may support mucosal immunity. The most commonly discussed option is serum-derived bovine immunoglobulin (SBI), marketed under the brand name EnteraGam. SBI provides IgG-enriched immunoglobulins derived from bovine serum. It is classified as a medical food (not a drug) and requires a prescription. The proposed mechanism is that bovine immunoglobulins survive gastric transit and bind pathogens and toxins in the gut lumen, partially compensating for the mucosal defense gap. Clinical studies in IBS-D and HIV enteropathy have shown modest symptom improvement, but data specifically in IgA-deficient SIBO patients are limited. Other supplements marketed for immune support (colostrum, lactoferrin, beta-glucans) have some preclinical evidence for mucosal immune modulation but lack robust clinical data in the SIBO context.

â„šī¸Serum-derived bovine immunoglobulin (SBI/EnteraGam) is a medical food that may provide supplemental immunoglobulins to the gut lumen. It requires a prescription and is not a replacement for immunoglobulin replacement therapy in CVID. Discuss it with your gastroenterologist if you have IgA deficiency and recurrent SIBO.

Frequently Asked Questions

Should every SIBO patient get immunoglobulin testing?

Not necessarily. Immunoglobulin testing is most valuable for patients with recurrent SIBO that relapses despite appropriate antibiotic and prokinetic therapy, patients with a history of frequent infections, or patients with autoimmune conditions. For a first SIBO episode that responds to treatment, immune testing is usually not the priority.

Can I order immunoglobulin testing on my own?

In some states and countries, you can order a serum immunoglobulin panel through direct-to-consumer lab services. However, interpreting the results requires medical context. An abnormal result should always be discussed with a physician who can evaluate the pattern, order confirmatory tests, and determine appropriate next steps.

Does immunoglobulin replacement therapy help with SIBO?

Immunoglobulin replacement (IVIG or subcutaneous Ig) is used for CVID and replaces IgG. It does not directly replace IgA. In CVID patients with SIBO, immunoglobulin replacement reduces overall infection burden and may indirectly improve gut immune function. It is not used for isolated IgA deficiency.

What is the difference between serum IgA and fecal sIgA?

Serum IgA measures the IgA circulating in your blood. Fecal sIgA measures the secretory IgA produced by gut mucosal cells and released into the intestinal lumen. They usually correlate, but discrepancies exist. A patient can have normal serum IgA with low fecal sIgA, indicating mucosal-specific immune impairment.

âš ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.

Key Takeaways

  1. 1A serum immunoglobulin panel is a simple, widely available blood test that should be considered in patients with recurrent SIBO.
  2. 2Low IgA with normal IgG and IgM points to selective IgA deficiency. Low IgG with low IgA and/or IgM suggests CVID and warrants immunology referral.
  3. 3Fecal sIgA is a functional mucosal marker available through specialty labs but has less standardized reference ranges.
  4. 4Do not self-diagnose based on immunoglobulin levels alone. Patterns require clinical interpretation and sometimes additional testing (vaccine response, lymphocyte subsets).
  5. 5If immune deficiency is confirmed, management includes treating SIBO episodes, prokinetic support, monitoring associated conditions, and sometimes immunoglobulin replacement.

Sources & References

  1. 1.Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies - Tangye SG et al., Journal of Clinical Immunology (2020)
  2. 2.Common variable immunodeficiency: diagnosis, management, and treatment - Bonilla FA et al., Journal of Allergy and Clinical Immunology (2016)
  3. 3.Serum-derived bovine immunoglobulin/protein isolate in the management of patients with IBS-D - Wilson D et al., World Journal of Gastroenterology (2013)
  4. 4.Selective IgA deficiency: prevalence, etiology, and clinical features - Yazdani R et al., Journal of Clinical Immunology (2017)

Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult with a qualified healthcare professional before making changes to your diet, medications, or health regimen. GLP1Gut is a tracking tool, not a medical device.

Figure Out What's Actually Triggering You

An AI-powered meal and symptom tracker that connects what you eat to how you feel, built specifically for people on GLP-1 medications experiencing digestive side effects.